Eiry Roberts - 04 Nov 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Medical Officer
Issuer ticker: NBIX
Reported as of: 04 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Nov 2026, 16:10:31 UTC
Prior SEC filing: 07 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Filing notes and source

Key filing fact

Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 05 Nov 2026.

Key facts

This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Nov 2026, 16:10.

Change

Previous filing in this sequence was filed on 07 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727606 Primary reporting owner

ROBERTS EIRY

Relationship: Chief Medical Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 05 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Stock Option

Award

Transaction value
Shares: +8,314
Change %
Price: $0.000000^*
Shares after: 8,314
Date: 04 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,314
Exercise price: $166.05
Footnotes: F1

NBIX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +1,506
Change %
Price: $0.000000^*
Shares after: 1,506
Date: 04 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,506
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 4, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

The Restricted Stock Units will settle annually at 1/4 of the units settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.